| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
May 15, 2012 |
|
|
| |
|
|
| |
|
|
|
The, Stevenage
2012-07-05
09.30 Registration and coffee
10.00 Introduction
Ken Leiper, Chairman, Joint Pharmaceutical Analysis Group
Chairman: To be advised
10.10 Practical case studies in method development: keep it simple
Garry Scrivens, Pfizer
10.55 A regulator’s expectations on method development in the dossier
Dr Amina Khalid, MHRA
11.40 Tea break
12.00 Application of a 6 sigma approach to the development of methods
Dave Holt, AstraZeneca
12.45 Lunch
13.45 HPLC/UPLC; new and novel column technologies and how this is
influencing method development choices
Mark Parry, Melbourn Scientific
14.30 Is the best method always the best method?? Just because you can
develop a fantastic method with all the latest technologies, should you?
Speaker to be confirmed
15.15 Tea break
15.35 Advances in in-silico method development
Speaker to be confirmed
16.20 Close
|
|
|
|
|
|
|
|
Organized by:
|
|
The Joint Pharmaceutical Analysis Group |
|
|
Invited Speakers:
|
|
Please follow this link to view the speakers on the program: http://www.jpag.org/content/info/2012-07-05/Brochure.pdf
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2012-06-22
|
|
|
|
|
|
|
|
Registration:
|
|
To register please follow this link: http://www.jpag.org/?p=meetings&r=10&lang=EN&sid=20120515142657559217
|
|
|
E-mail:
|
|
events@rpharms.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|